Vista Pharmaceuticals Reports Q3 Loss of Rs. 838.25 Lakhs, Recognizes ECL of INR 205.43 Lakhs

Vista Pharmaceuticals Limited reported its financial results for the quarter and nine months ended 31st December 2025, according to the Listing Obligations and Disclosure requirements regulations, 2015. The company's revenue for the current quarter was Rs. 241.82 Lakhs, compared to Rs. 255.50 Lakhs for the corresponding quarter of the previous year. The company recognized a provision for Expected Credit Loss (ECL) amounting to INR 205.43 lakhs against its long-pending trade receivables. The company incurred a net loss for the quarter ended 31st December amounting to Rs. (838.25) Lakhs, and has outstanding statutory liabilities which have not been paid as on the quarter end.